BACKGROUND: Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamazine and albendazole) or DA (diethylcarbamazine and albendazole) in India. METHODOLOGY/PRINCIPAL FINDINGS: This two-armed, open-labelled, block randomised, community study was conducted in LF endemic villages in Yadgir district, Karnataka, India. Consenting participants ≥5 years of age were tested for circulating filarial antigenemia (CFA) and microfilaremia (Mf) before treatment with a single oral dose of IDA or DA. Adverse events (AEs) were monitored actively for two days and passively for five more days. Persons with positive CFA or Mf tests at baseline were retested 12-months post-treatment to assess treatment efficacy. Baseline CFA and Mf-rates were 26.4% and 6.9% in IDA and 24.5% and 6.4% in DA villages respectively. 4758 and 4160 participants receivedIDA and DA. Most AEs were mild after both treatments; fewer than 0.1% of participants experienced AEs with severity > grade 1. No serious AEs were observed. Fever, headache and dizziness were the most common AEs. AE rates were slightly higher after IDA than DA (8.3% vs. 6.4%, P<0.01). AEs were more frequent in females and Mf-positives after either treatment, but significantly more frequent after IDA (40.5% vs 20.2%, P < 0.001). IDA was more effective for clearing Mf than DA (84% vs. 61.8%, P < 0.001). Geometric mean Mf counts per 60μl in retested Mf-positives decreased by 96.4% from 11.8 after IDA and by 90.0% from 9.5 after DA. Neither treatment was effective for clearing CFA. CONCLUSIONS/SIGNIFICANCE:IDA had an acceptable safety profile and was more effective for clearing Mf than DA. With adequate compliance and medical support to manage AEs, IDA has the potential to accelerate LF elimination in India. TRIAL REGISTRATION: Clinical Trial Registry of India (CTRI No/2016/10/007399).
RCT Entities:
BACKGROUND: Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamazine and albendazole) or DA (diethylcarbamazine and albendazole) in India. METHODOLOGY/PRINCIPAL FINDINGS: This two-armed, open-labelled, block randomised, community study was conducted in LF endemic villages in Yadgir district, Karnataka, India. Consenting participants ≥5 years of age were tested for circulating filarial antigenemia (CFA) and microfilaremia (Mf) before treatment with a single oral dose of IDA or DA. Adverse events (AEs) were monitored actively for two days and passively for five more days. Persons with positive CFA or Mf tests at baseline were retested 12-months post-treatment to assess treatment efficacy. Baseline CFA and Mf-rates were 26.4% and 6.9% in IDA and 24.5% and 6.4% in DA villages respectively. 4758 and 4160 participants received IDA and DA. Most AEs were mild after both treatments; fewer than 0.1% of participants experienced AEs with severity > grade 1. No serious AEs were observed. Fever, headache and dizziness were the most common AEs. AE rates were slightly higher after IDA than DA (8.3% vs. 6.4%, P<0.01). AEs were more frequent in females and Mf-positives after either treatment, but significantly more frequent after IDA (40.5% vs 20.2%, P < 0.001). IDA was more effective for clearing Mf than DA (84% vs. 61.8%, P < 0.001). Geometric mean Mf counts per 60μl in retested Mf-positives decreased by 96.4% from 11.8 after IDA and by 90.0% from 9.5 after DA. Neither treatment was effective for clearing CFA. CONCLUSIONS/SIGNIFICANCE:IDA had an acceptable safety profile and was more effective for clearing Mf than DA. With adequate compliance and medical support to manage AEs, IDA has the potential to accelerate LF elimination in India. TRIAL REGISTRATION: Clinical Trial Registry of India (CTRI No/2016/10/007399).
Authors: Cédric B Chesnais; François Missamou; Sébastien D S Pion; Jean Bopda; Frédéric Louya; Andrew C Majewski; Gary J Weil; Michel Boussinesq Journal: Am J Trop Med Hyg Date: 2013-09-09 Impact factor: 2.345
Authors: Michael A Irvine; Wilma A Stolk; Morgan E Smith; Swaminathan Subramanian; Brajendra K Singh; Gary J Weil; Edwin Michael; T Deirdre Hollingsworth Journal: Lancet Infect Dis Date: 2016-12-22 Impact factor: 25.071
Authors: Christopher L King; James Suamani; Nelly Sanuku; Yao-Chieh Cheng; Samson Satofan; Brooke Mancuso; Charles W Goss; Leanne J Robinson; Peter M Siba; Gary J Weil; James W Kazura Journal: N Engl J Med Date: 2018-11-08 Impact factor: 91.245
Authors: Gary J Weil; Joshua Bogus; Michael Christian; Christine Dubray; Yenny Djuardi; Peter U Fischer; Charles W Goss; Myra Hardy; Purushothaman Jambulingam; Christopher L King; Vijesh Sridhar Kuttiat; Kaliannagounder Krishnamoorthy; Moses Laman; Jean Frantz Lemoine; Katiuscia K O'Brian; Leanne J Robinson; Josaia Samuela; Kenneth B Schechtman; Anita Sircar; Adinarayanan Srividya; Andrew C Steer; Taniawati Supali; Swaminathan Subramanian Journal: PLoS Med Date: 2019-06-24 Impact factor: 11.069
Authors: Wilma A Stolk; Joaquin M Prada; Morgan E Smith; Periklis Kontoroupis; Anneke S de Vos; Panayiota Touloupou; Michael A Irvine; Paul Brown; Swaminathan Subramanian; Marielle Kloek; E Michael; T Deirdre Hollingsworth; Sake J de Vlas Journal: Clin Infect Dis Date: 2018-06-01 Impact factor: 9.079
Authors: Myra Hardy; Josaia Samuela; Mike Kama; Meciusela Tuicakau; Lucia Romani; Margot J Whitfeld; Christopher L King; Gary J Weil; Anneke C Grobler; Leanne J Robinson; John M Kaldor; Andrew C Steer Journal: PLoS Negl Trop Dis Date: 2020-03-16
Authors: Livingstone Tavul; Moses Laman; Cade Howard; Bethuel Kotty; Anna Samuel; Catherine Bjerum; Kobie O'Brian; Steven Kumai; Matthew Amuga; Lina Lorry; Zebedee Kerry; Melvin Kualawi; Stephan Karl; Leo Makita; Lucy N John; Sibauk Bieb; James Wangi; Gary J Weil; Charles W Goss; Daniel J Tisch; William Pomat; Christopher L King; Leanne J Robinson Journal: PLoS Negl Trop Dis Date: 2022-02-09
Authors: Purushothaman Jambulingam; Swaminathan Subramanian; Kaliannagounder Krishnamoorthy; Taniawati Supali; Peter Fischer; Christine Dubray; Carl Fayette; Jean Frantz Lemoine; Moses Laman; Christopher King; Josaia Samuela; Myra Hardy; Gary J Weil Journal: Am J Trop Med Hyg Date: 2022-03-15 Impact factor: 3.707
Authors: Moses Laman; Livingstone Tavul; Stephan Karl; Bethuel Kotty; Zebede Kerry; Stephen Kumai; Anna Samuel; Lina Lorry; Lincoln Timinao; S Cade Howard; Leo Makita; Lucy John; Sibauk Bieb; James Wangi; Jeffrey M Albert; Michael Payne; Gary J Weil; Daniel J Tisch; Catherine M Bjerum; Leanne J Robinson; Christopher L King Journal: Lancet Infect Dis Date: 2022-05-06 Impact factor: 71.421